HTA Quarterly Fall 2026

In this edition, we explore how increasingly interconnected pricing policies, including Most Favored Nation pricing and international reference pricing, are raising the stakes for how manufacturers plan launches and demonstrate value across markets. We also examine new U.S.-focused research on the higher out-of-pocket burden faced by breast cancer patients with mental health comorbidities, underscoring the importance of patient-centered benefit design and targeted affordability policies. Rounding out this edition, we look at the growing role of German claims data in generating real-world evidence to support HTA, market access, and lifecycle decision-making.